For many, the phrase "stroke of the eye" sounds figurative, but for Dr. Jagannadha "Jay" Avasarala of UK HealthCare, it is a life-or-death medical emergency. His new study, published in The American Journal of Emergency Medicine, highlights a critical gap in how emergency departments diagnose giant cell arteritis (GCA), a condition that can cause sudden, irreversible blindness if not treated immediately. GCA, also known as temporal arteritis, is an autoimmune disorder that inflames large arteries, particularly those in the head. It commonly affects adults over 50 and can lead to severe complications including vision loss, strokes, and aortic aneurysms. The most urgent threat is sudden vision impairment due to blocked blood flow to the eye—what Avasarala calls a "stroke of the eye." Using data from the University of Kentucky Medical Center and a national health database representing nearly 300 million patients, Avasarala and his team analyzed how often emergency departments tested for GCA in patients with acute vision changes. The findings were alarming: over 60% of such patients received no testing for GCA, with rates reaching as high as 94% in certain demographic groups. Even when testing occurred, many patients had already been given steroids—treatment that can mask the condition and lead to false-negative results. The key to accurate diagnosis is testing before steroids are administered. Avasarala’s research identifies temporal artery ultrasound (TAUS) as a game-changing solution. This noninvasive, real-time imaging test can detect arterial inflammation quickly and safely in the emergency department. In a review of over 700 patients, TAUS proved to be the strongest predictor of a correct GCA diagnosis—outperforming the traditional temporal artery biopsy, which is invasive, time-consuming, and not available in real time. "Ultrasound offers real-time information," Avasarala said. "It's fast, safe, and accessible—exactly what we need when every minute counts." The study calls for integrating TAUS into emergency department protocols worldwide. Doing so could drastically reduce delays in diagnosis and treatment, preventing blindness in patients who might otherwise lose their sight before reaching a specialist. Avasarala is already advancing the vision further. In a companion paper published in the Journal of Rheumatology, he and colleagues propose using artificial intelligence and cloud-based systems with portable handheld ultrasound devices to enable real-time GCA diagnosis—even in remote or underserved areas. "Blindness from this disease is preventable," Avasarala said. "We have the technology. Now we need to bring it to where the patients are—whether in an emergency room, an ambulance, or a rural clinic." He advocates for treating GCA like a stroke emergency, with standardized protocols that ensure rapid diagnosis and treatment. Just as hospitals follow guidelines for stroke care, similar systems should be established for GCA. "If we can diagnose a cerebrovascular stroke in real time, we can diagnose a stroke of the eye the same way," Avasarala said. "No one should lose their vision when the tools to prevent it are right in front of us."